June 16 (Reuters) - Martek Biosciences Corp MATK.O, a health and nutritional supplements maker, said the European Patent Office upheld its arachidonic (ARA) patent granted in 2007, but with narrower claims.
“The claims were narrowed by adding a specified ratio of ARA to eicosapentaenoic acid, or EPA, in infant formula applications,” the company said in a regulatory filing.
The narrower claims cover the use of Martek’s blended microbial oil products in infant formula, but does not cover microbial ARA when blended with certain fish oils in infant formula, the company said in a regulatory filing, it added.
Martek plans to appeal the decision to the board of appeals of the European Patent Office.
Shares of Martek Biosciences closed at $21.57 Tuesday on Nasdaq. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Ratul Ray Chaudhuri)